Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

AIDS (London, England) - 2 Jan 2006

Vora Samir, Marcelin Anne-Geneviève, Günthard Huldrych F, Flandre Philippe, Hirsch Hans H, Masquelier Bernard, Zinkernagel Annelies, Peytavin Gilles, Calvez Vincent, Perrin Luc, Yerly Sabine

Abstract excerpt

OBJECTIVE: To develop a clinically relevant genotypic resistance score for boosted atazanavir (ATV) in protease inhibitor-experienced patients. METHODS: At baseline, 62 patients with HIV-1 RNA > 1000 copies/ml switched to a boosted ATV regimen (300 mg ATV, 100 mg ritonavir once daily); two were excluded from analysis at 3 months as they had undetectable plasma ATV. The impact of baseline protease mutations on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Oligopeptides

Share to Pyridines

Share to Reverse Transcriptase Inhibitors

Share to Ritonavir

Source

Identifiers

PMID: 16327317
DOI: 10.1097/01.aids.0000196179.11293.fc

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.PMID 16327317Read ↗

Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.Semantic proximity Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).Semantic proximity Read ↗

Clinically relevant interpretation of genotype for resistance to abacavir.Semantic proximity Read ↗

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.Semantic proximity Read ↗

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).Semantic proximity Read ↗

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.Semantic proximity Read ↗

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.Semantic proximity Read ↗

Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.Semantic proximity Read ↗

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.Semantic proximity Read ↗

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Semantic proximity Read ↗

Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.